"We are pleased to receive approval for the clinical trial of Human Prothrombin Complex," said Mr. Stanley Wong, CEO of China Biologic. "Our approval is a significant milestone in our research and development of plasma factor products and reflection of our ongoing efforts to upgrade our product portfolio."
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating
to the business of China Biologic Products, Inc. and its subsidiary
companies. All statements, other than statements of historical fact
included herein are "forward-looking statements," including statements
regarding: the ability of the Company to expand its list of potential
investors and increase its liquidity and visibility in the market or
otherwise achieve its commercial objectives; the business strategy, plans
and objectives of the Company and its subsidiaries; and any other
statements of non-historical information. These forward-looking statements
are often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, involve known and unknown
risks and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are re
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved